Acrobiosystems Co

Acrobiosystems Co Working Capital

The Working Capital of Acrobiosystems Co (301080.SZ) as of Nov 15, 2026 is 205.99 M CNY. In the previous year, Working Capital was 201.01 M CNY — a change of 2.48% (higher).

Working Capital

205.99 MCNY

YoY

2.48%

Last updated:

Working Capital of Acrobiosystems Co is 2025 205.99 M CNY. Working Capital of Acrobiosystems Co was 2024 201.01 M CNY. It decreases by 2.48% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Working Capital of Acrobiosystems Co is 205.99 M CNY in 2025.

Working Capital of Acrobiosystems Co changed from 201.01 M CNY to 205.99 M CNY, representing a 2.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co